RPTX Relative Valuation
RPTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RPTX is overvalued; if below, it's undervalued.
Historical Valuation
Repare Therapeutics Inc (RPTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.51. The fair price of Repare Therapeutics Inc (RPTX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.23
Fair
-2.48
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Repare Therapeutics Inc. (RPTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.78. The thresholds are as follows: Strongly Undervalued below -10.66, Undervalued between -10.66 and -6.72, Fairly Valued between 1.16 and -6.72, Overvalued between 1.16 and 5.10, and Strongly Overvalued above 5.10. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.49
EV/EBIT
Repare Therapeutics Inc. (RPTX) has a current EV/EBIT of 0.49. The 5-year average EV/EBIT is -2.48. The thresholds are as follows: Strongly Undervalued below -10.24, Undervalued between -10.24 and -6.36, Fairly Valued between 1.39 and -6.36, Overvalued between 1.39 and 5.27, and Strongly Overvalued above 5.27. The current Forward EV/EBIT of 0.49 falls within the Historic Trend Line -Fairly Valued range.
13.99
PS
Repare Therapeutics Inc. (RPTX) has a current PS of 13.99. The 5-year average PS is 70.14. The thresholds are as follows: Strongly Undervalued below -182.40, Undervalued between -182.40 and -56.13, Fairly Valued between 196.41 and -56.13, Overvalued between 196.41 and 322.68, and Strongly Overvalued above 322.68. The current Forward PS of 13.99 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Repare Therapeutics Inc. (RPTX) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.62. The thresholds are as follows: Strongly Undervalued below -46.83, Undervalued between -46.83 and -23.72, Fairly Valued between 22.48 and -23.72, Overvalued between 22.48 and 45.58, and Strongly Overvalued above 45.58. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Repare Therapeutics Inc. (RPTX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.66. The thresholds are as follows: Strongly Undervalued below -57.64, Undervalued between -57.64 and -28.49, Fairly Valued between 29.82 and -28.49, Overvalued between 29.82 and 58.97, and Strongly Overvalued above 58.97. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Repare Therapeutics Inc (RPTX) has a current Price-to-Book (P/B) ratio of 0.83. Compared to its 3-year average P/B ratio of 1.00 , the current P/B ratio is approximately -17.08% higher. Relative to its 5-year average P/B ratio of 1.96, the current P/B ratio is about -57.55% higher. Repare Therapeutics Inc (RPTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -68.18%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -44.25% , the current FCF yield is about -100.00% lower.
0.83
P/B
Median3y
1.00
Median5y
1.96
-75.20
FCF Yield
Median3y
-68.18
Median5y
-44.25
Competitors Valuation Multiple
The average P/S ratio for RPTX's competitors is 0.00, providing a benchmark for relative valuation. Repare Therapeutics Inc Corp (RPTX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RPTX increased by 70.23% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 11.62M.
The secondary factor is the Margin Expansion, contributed -126.77%to the performance.
Overall, the performance of RPTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Repare Therapeutics Inc (RPTX) currently overvalued or undervalued?
What is Repare Therapeutics Inc (RPTX) fair value?
How does RPTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Repare Therapeutics Inc (RPTX) as of Dec 05 2025?
What is the current FCF Yield for Repare Therapeutics Inc (RPTX) as of Dec 05 2025?
What is the current Forward P/E ratio for Repare Therapeutics Inc (RPTX) as of Dec 05 2025?